Compare Goldman Sachs Group Inc (GS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Goldman Sachs Group Inc trades at $881.19 (market cap $255.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Goldman Sachs Group Inc is far larger — about 34.8× Spyre Therapeutics Inc. Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.28% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 100 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GS | SYRE | |
|---|---|---|
Market Cap | $255.86B | $7.35B |
Volume | 3,405,238 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $1.15K | $108.92 |
52-Week Low | $744.60 | $22.18 |
Typical Hold Time | 100 Days | 0 Days |
Enterprise Value | $255.77B | $6.35B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
